Julie M. Vose

Julie M. Vose

Hematology | Oncology
505 S 45th St.
Omaha, NE 68105

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 251 publications

Proteome landscape of B-cell malignancies identifies mantle cell lymphoma protein signature.

Proteome landscape of B-cell malignancies identifies mantle cell lymphoma protein signature.

Journal: bioRxiv : the preprint server for biology
Published: March 23, 2026

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

Journal: Blood
Published: February 05, 2026

Persistence of PET scan positivity after chemoimmunotherapy for DLBCL.

Persistence of PET scan positivity after chemoimmunotherapy for DLBCL.

Journal: Blood advances
Published: December 10, 2025

Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma-GATA3 molecular subgroup.

Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma-GATA3 molecular subgroup.

Journal: Science advances
Published: October 17, 2025

Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma-GATA3 molecular subgroup.

Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma-GATA3 molecular subgroup.

Journal: Science advances
Published: October 17, 2025

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: October 09, 2025

Benchmarking the Current Landscape: Insights From an Association of American Cancer Institutes Survey on Academic Cancer Service Lines.

Benchmarking the Current Landscape: Insights From an Association of American Cancer Institutes Survey on Academic Cancer Service Lines.

Journal: JCO oncology practice
Published: September 24, 2025

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

Journal: The Lancet. Haematology
Published: September 18, 2025

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Journal: Blood advances
Published: June 18, 2025

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study.

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study.

Journal: Blood advances
Published: June 18, 2025

Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial.

Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial.

Journal: Annals of hematology
Published: May 16, 2025

CLO25-054: Long Term Follow Up of Patients Undergoing High Dose Chemotherapy and Autologous or Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma.

CLO25-054: Long Term Follow Up of Patients Undergoing High Dose Chemotherapy and Autologous or Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
Showing 1-12 of 251

Last Updated: 09/26/2026